Presentations pertaining to tebipenem HBr and the epidemiology and management of cUTI:
1. Title: Tebipenem in vitro activity against a collection of pathogens responsible for urinary tract infections in the US
Presenting Author:
Date:
Poster Session: A1. Novel Agents
Poster Number: 1057
2. Title: In vitro activity of tebipenem against clinically significant gram-negative bacteria isolated from patients with cancer
Presenting Author:
Date:
Poster Session: A1. Novel Agents
Poster Number: 1069
3. Title: Development of tebipenem MIC antimicrobial susceptibility test for gram-negative bacteria on MicroScan dried gram-negative MIC panels
Presenting Author:
Date:
Poster Session: A1. Novel Agents
Poster Number: 1079
4. Title: Pharmacokinetics-pharmacodynamics evaluation of tebipenem pivoxil hydrobromide using the 10-day hollow-fiber in vitro infection model
Presenting Author:
Date:
Poster Session: A2. PK/PD Studies
Poster Number: 1095
5. Title: Population pharmacokinetic analyses for tebipenem after the administration of tebipenem pivoxil hydrobromide
Presenting Author:
Date:
Poster Session: A2. PK/PD Studies
Poster Number: 1105
6. Title: Oral tebipenem as step-down therapy following intravenous ertapenem in a 7-day hollow-fiber in vitro model
Author:
Date:
Poster Session: A2. PK/PD Studies
Poster Number: 1113
7. Title: Absorption, metabolism, and excretion of [14C]-tebipenem pivoxil hydrobromide (TBP-PI-HBr) following a single oral dose in healthy male subjects
Presenting Author:
Date:
Poster Session: A2. PK/PD Studies
Poster Number: 1120
8. Title: Bioequivalence of two formulations of oral tebipenem-pivoxil hydrobromide in healthy subjects
Presenting Author:
Date:
Poster Session: A2. PK/PD Studies
Poster Number: 1121
9. Title: Effect of aluminum hydroxide/magnesium hydroxide/simethicone and omeprazole on the pharmacokinetics of tebipenem pivoxil hydrobromide (TBP-PI-HBr) in healthy adult subjects
Presenting Author:
Date:
Poster Session: A2. PK/PD Studies
Poster Number: 1122
10. Title: In vitro activity of tebipenem and comparators against Enterobacterales collected from patients with bloodstream infections as part of the 2019 global STEWARD surveillance program
Presenting Author:
Date:
Poster Session: A3. Resistance mechanisms
Poster Number: 1226
11. Title: Molecular epidemiology of Escherichia coli causing urinary tract infections in
Presenting Author:
Date:
Poster Session: A3. Resistance mechanisms
Poster Number: 1254
12. Title: An evaluation of tebipenem in vitro activity against a panel of Pseudomonas aeruginosa isolates with Efflux, AmpC, and OprD Mutations
Presenting Author:
Date:
Poster Session: A3. Resistance mechanisms
Poster Number: 1281
13. Title: In vitro analysis of AmpC β-lactamase induction by tebipenem in Enterobacterales and Pseudomonas aeruginosa
Presenting Author:
Date:
Poster Session: A6. New drug development (formerly L3)
Poster Number: 1036
14. Title: In vitro activity of tebipenem, an orally available carbapenem agent, against a collection of surveillance Gram-positive clinical isolates
Presenting Author: SJ Ryan Arends, PhD (Scientist,
Date:
Poster Session: A6. New drug development (formerly L3)
Poster Number: 1038
15. Title: In vitro activity of tebipenem against a recent collection of fastidious organisms recovered from respiratory tract infections
Presenting Author: SJ Ryan Arends, PhD (Scientist,
Date:
Poster Session: A6. New drug development (formerly L3)
Poster Number: 1041
16. Title: In vitro activity of tebipenem against relevant clinical isolates in the presence of pulmonary surfactant
Presenting Author: SJ Ryan Arends, PhD (Scientist,
Date:
Poster Session: A6. New drug development (formerly L3)
Poster Number: 1044
17. Title: Medicare spending on urinary tract infections: a retrospective database analysis
Presenting Author:
Date:
Poster Session: C11. UTIs
Poster Number: 1416
18. Title: High prevalence of fluoroquinolone-resistant urinary tract infection among US emergency department patients diagnosed with UTI, 2018-2020
Presenting Author:
Date:
Poster Session: C11. UTIs
Poster Number: 1419
19. Title: Descriptive epidemiology of UTI hospitalizations in the US, 2018
Presenting Author:
Date:
Poster Session: C11. UTIs
Poster Number: 1420
20. Title: Empiric antimicrobial prescribing for urinary tract infections in patients discharged from the emergency department
Presenting Author:
Date:
Poster Session: C11. UTIs
Poster Number: 1426
21. Title: Healthcare resource utilization during hospitalizations with UTI in the US, 2018
Presenting Author:
Date:
Poster Session: C11. UTIs
Poster Number: 1427
22. Title: Descriptive epidemiology of emergency department visits with cUTI in the US, 2012-2018
Presenting Author:
Date:
Poster Session: C11. UTIs
Poster Number: 1430
23. Title: Epidemiology and 12-month antibiotic use in the outpatient setting among adult patients with complicated urinary tract infections: a retrospective database analysis
Presenting Author:
Date:
Poster Session: C11. UTIs
Poster Number: 1439
About Spero Therapeutics
Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.
Spero is also developing SPR720 as a novel oral therapy product candidate for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.
Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting.
For more information, visit https://sperotherapeutics.com.
Investor Relations Contact:
Vice President, Head of Investor Relations
Tjenkins@sperotherapeutics.com
(617) 798-4039
Media Contact:
media@sperotherapeutics.com
Source: Spero Therapeutics, Inc.